Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Equity Ratio: 2019-2023

Historic Equity Ratio for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to -0.12.

  • ADC Therapeutics' Equity Ratio fell 158.89% to -0.12 in Q3 2023 from the same period last year, while for Sep 2023 it was -0.12, marking a year-over-year decrease of 158.89%. This contributed to the annual value of 0.16 for FY2022, which is 39.78% down from last year.
  • Latest data reveals that ADC Therapeutics reported Equity Ratio of -0.12 as of Q3 2023, which was down 585.40% from -0.02 recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Equity Ratio ranged from a high of 147.20 in Q3 2020 and a low of -0.12 during Q3 2023.
  • Its 3-year average for Equity Ratio is 0.23, with a median of 0.22 in 2022.
  • In the last 5 years, ADC Therapeutics' Equity Ratio rose by 0.03% in 2021 and then tumbled by 158.89% in 2023.
  • ADC Therapeutics' Equity Ratio (Quarterly) stood at 0.81 in 2019, then reached 147.20 in 2020, then plummeted by 99.80% to 0.27 in 2021, then tumbled by 39.78% to 0.16 in 2022, then tumbled by 158.89% to -0.12 in 2023.
  • Its Equity Ratio was -0.12 in Q3 2023, compared to -0.02 in Q2 2023 and 0.08 in Q1 2023.